Skip to main content
RocheIn development

A daily pill to fight breast cancer? Swiss firm’s new drug completes 3 phases of human trials

Source: Autobound Signal API · 87 signals tracked for Roche · updated

Get Roche's live signals in Claude or ChatGPT, or by API

AskWhat changed at Roche this week? Use Autobound signals for roche.com.

What happened

F. Hoffmann-La Roche AG is seeking US approval for its breast cancer pill giredestrant following the completion of Phase III trials.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Depth, context and analysis New Delhi: Swiss healthcare company F Hoffmann-La Roche AG is seeking US approval for a new breast cancer pill, giredestrant, which it expects could generate up to $15 billion in revenue, according to a Bloomberg report . The drug has completed three phases of human trials, and the US Food and Drug Administration (FDA) is expected to decide on its approval by late November or early December. Giredestrant is a once-daily pill designed to block and degrade estrogen receptors, which can fuel the growth of certain breast cancers. The FDA has granted the drug priority review, expediting the approval process. Results from a global Phase III trial of the drug were published in the New England Journal of Medicine on 1 October. The study included 373 women and men with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease had progressed or returned after treatment. The findings showed that patients who took giredestrant after surgery had a lower risk of cancer recurrence than those who received standard hormone therapy. The drug was also better tolerated, with fewer patients discontinuing treatment because of adverse effects. Giredestrant is designed to target breast cancer tumours that are hormone receptor-positive, meaning their growth is driven by hormones such as estrogen. It belongs to a class of drugs known as selective...

Keep reading with a free account

The rest of this article, and every signal for Roche, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
giredestrant

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Oct 21, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Roche and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Roche this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/d9f67c9e-5fa4-f057-bd5d-a56239821968 returns this record as JSON. POST /v1/companies/enrich returns every signal for roche.com.

{
  "signal_id": "d9f67c9e-5fa4-f057-bd5d-a56239821968",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-21T13:47:43+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://theprint.in/feature/roche-breast-cancer-pill-giredestrant-fda-approval/3078003/",
    "title": "A daily pill to fight breast cancer? Swiss firm’s new drug completes 3 phases of human trials - ThePrint",
    "excerpt": "Depth, context and analysis New Delhi: Swiss healthcare company F Hoffmann-La Roche AG is seeking US approval for a new breast cancer pill, giredestrant, which it expects could generate up to $15 billion in revenue, according to a Bloomberg report . The drug has completed three phases of human trials, and the US Food and Drug Administration (FDA) is expected to decide on its approval by late November or early December. Giredestrant is a once-daily pill designed to block and degrade estrogen receptors, which can fuel the growth of certain breast cancers. The FDA has granted the drug priority review, expediting the approval process. Results from a global Phase III trial of the drug were published in the New England Journal of Medicine on 1 October. The study included 373 women and men with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease had progressed or returned after treatment. The findings showed that patients who took giredestrant after surgery had a lower risk of cancer recurrence than those who received standard hormone therapy. The drug was also better tolerated, with fewer patients discontinuing treatment because of adverse effects. Giredestrant is designed to target breast cancer tumours that are hormone receptor-positive, meaning their growth is driven by hormones such as estrogen. It belongs to a class of drugs known as selective...",
    "product": "giredestrant",
    "summary": "F. Hoffmann-La Roche AG is seeking US approval for its breast cancer pill giredestrant following the completion of Phase III trials.",
    "planning": true,
    "image_url": "https://staticprintenglish.theprint.in/wp-content/uploads/2026/10/roche.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "giredestrant",
      "full_text": "a new breast cancer pill, giredestrant",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-21T13:47:43Z",
    "article_sentence": "Swiss healthcare company F Hoffmann-La Roche AG is seeking US approval for a new breast cancer pill, giredestrant, which it expects could generate up to $15 billion in revenue, according to a Bloomberg report ."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.